Zoetis study shows Simparica Trio outperforms NexGard Plus against resistant heartworm isolate

• Zoetis disclosed peer-reviewed lab-study results in Parasites & Vectors comparing Simparica Trio with NexGard Plus against resistant heartworm.
• Simparica Trio prevented adult heartworm infection in more dogs than NexGard Plus in a controlled, head-to-head challenge study.
• Findings point to dosage-driven differences in protection where drug-resistant heartworm is circulating, with implications for product selection and compliance.
• Publication follows an earlier head-to-head study in a different resistant isolate that also favored Simparica Trio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005782418) on October 06, 2026, and is solely responsible for the information contained therein.